Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-15 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| SGN-15 (cBR96-doxorubicin immunoconjugate) | DRUG | - |
| Taxotere (docetaxel) | DRUG | - |
| SGN-15 | DRUG | - |
| Docetaxel | DRUG | - |
BRIEF: Patients must have pathologically confirmed prostate cancer, which is refractory to hormone therapy. There must be evidence of advancing disease, determined by increasing bidimensional or unidimensional measurable tumor or an increasing PSA with documented metastatic disease. Patients must ...
SGN-15 is an investigational small molecule being studied for the treatment of certain cancers, including non-small cell lung carcinoma and prostate cancer. It is being developed by Pfizer, Inc. (NYSE: PFE).
SGN-15 is an antibody-drug conjugate, but its specific molecular target is not disclosed in available information. It is being studied in oncology for its potential to treat non-small cell lung carcinoma and prostate cancer.
SGN-15 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE.
SGN-15 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed, but the drug is not yet available for commercial use.
SGN-15 has been studied in three completed Phase 2 trials. NCT00031187 evaluated SGN-15 in hormone refractory prostate cancer with 160 participants. NCT00051571 and NCT00086333 studied SGN-15 combined with docetaxel in non-small cell lung carcinoma, with 60 and 30 participants respectively.
Yes, SGN-15 is an antibody-drug conjugate, a type of targeted therapy that links a monoclonal antibody to a cytotoxic drug. It is being investigated for its potential to deliver chemotherapy directly to cancer cells.